GlassScriptPhysician profile
Monica A Smith
NPI 1639280399
$6,704.25
in general payments reported to CMS, 2019-2025
20 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,125 · 2022: $1,231 · 2023: $902 · 2024: $1,212 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,913.90 | 2021-2025 | |
| Alkermes, INC. | $891.97 | 2021-2025 | Aristada, Vivitrol, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $761.96 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $758.30 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $522.47 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $353.01 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $315.23 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $282.75 | 2021-2024 | Invega, Spravato |
| E.R. Squibb & Sons, L.L.C. | $256.16 | 2024-2025 | Cobenfy |
| Indivior INC. | $166.14 | 2023-2025 | Sublocade |
| Cvrx, INC. | $119.91 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $87.49 | 2024 | |
| Sunovion Pharmaceuticals INC. | $62.25 | 2021 | |
| Lundbeck LLC | $56.21 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $54.72 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $28.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.23 | 2022 | |
| Braeburn INC. | $17.77 | 2025 | Brixadi |
| Sage Therapeutics, LLC | $14.83 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.